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Background: The consequences of cancer and its treatment on health-related quality of life
(HRQL) and health care utilisation among elderly long-term cancer survivors have rarely
been studied. However, the impact can be different for older compared to younger patients
due to the higher prevalence of comorbid diseases, a higher risk of treatment-related com-
plications and because they often receive different therapies compared to younger
patients. Therefore, this study addressed the following questions; do HRQL and health care
utilisation differ between younger and elderly cancer survivors, and are those differences
age or disease related.
Methods: A population-based, cross-sectional survey among 1893 long-term survivors of
endometrial cancer, prostate cancer and non-Hodgkin’s lymphoma was conducted using
a cancer registry. HRQL was measured by the SF-36 and health care utilisation was mea-
sured with a self-reported questionnaire. Results were compared to a normative popula-
tion. Patients with disease progression were excluded resulting in a total number of 1112
patients to be analysed.
Results: Young non-Hodgkin lymphoma survivors (<70 years) reported lower vitality, bodily
pain and general health compared to the normative population while older (P70 years) sur-
vivors did not differ from the norm. Young lymphoma survivors experienced better phys-
ical functioning compared to older survivors. Young endometrial cancer survivors
experienced less bodily pain compared to the normative population while older survivors
did not differ from the norm. Young endometrial cancer survivors experienced better phys-
ical and role functioning compared to older survivors. Young prostate cancer survivors
reported less bodily pain compared to the norm while older survivors did not. Young pros-
tate cancer survivors reported higher scores on physical functioning compared to older sur-
vivors. Age, comorbid diseases, educational level and current occupation influenced HRQL
significantly. Both younger and older cancer survivors visited their medical specialist, but
not their GP, significantly more often compared to the age-matched general Dutch popula-
tion. Both younger and older cancer survivors only sporadically used additional care
services after cancer treatment.
Discussion: HRQL of older and younger survivors is comparable, with the exception of
physical functioning which is lower in older survivors. This difference in physical function-
ing was probably not caused by cancer because physical functioning among cancer survi-
vors did not differ much compared to an age-matched normative population. Both youngerer Ltd. All rights reserved.
esearch on Psychology in Somatic Diseases (CoRPS), Tilburg University, P.O. Box 90153, 5000
466 2715; fax: +31 (0) 13 466 2067.
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ically used additional care services after cancer treatment.
 2007 Elsevier Ltd. All rights reserved.1. Introduction 2. Patients and methodsDue to the increasing incidence of cancer in general, the age-
ing of the population and more effective cancer treatments
the prevalence of cancer is rising.1 Cancer is changing from a
life-threatening disease into a chronic condition.2 A large
number of cancer patients will therefore become long-term
survivors: i.e. those alive 5 years after initial diagnosis.3 Be-
cause the incidence of most types of cancer is age-dependent
and the risk of developing a tumour is progressively higher
with increasing age, the mean age of cancer survivors is
increasing. Based on data from the Netherlands Cancer Reg-
istry, the Dutch Cancer Society estimated that in the year
2000, the prevalence of cancer among patients older than 64
was about 215,000. This prevalence is expected to double to
430,000 in the year 2015.1 In younger cancer patients (15–64
year) these numbers are 149,000 and 273,000, respectively.
This illustrates the rapid increase in the numbers of elderly
patients who are either cured of their cancer or living with
it as a chronic disease.
Cancer and its treatment can have a significant effect on a
patient’s life during diagnosis and treatment but also years
after the treatment has been completed. For example, pros-
tate cancer patients had comparable health-related quality
of life (HRQL) scores but worse general health perceptions
and better mental health than an age-matched normative
population.4 In addition, long-term non-Hodgkin lymphoma
survivors experienced lower general health and felt less vital
compared to an age-matched normative sample.5 Finally,
endometrial cancer survivors treated with surgery and adju-
vant radiotherapy felt less vital compared to patients treated
with surgery alone.6
The consequences of these effects on HRQL and health care
utilisation among elderly long-term cancer survivors have
rarely been studied separately from results of younger cancer
survivors and additionally, elderly patients are often excluded
from clinical trials. However, the impact of cancer and its
treatment can be different for older compared to younger pa-
tients due to a number of reasons including the higher preva-
lence of comorbid diseases,7 a higher risk of treatment-related
complications8 and the fact that older patients often receive
different therapies7,9,10 compared to younger patients.
The aim of the present population-based study was to ob-
tain insight into the HRQL and health care utilisation of el-
derly long-term cancer survivors by comparing our data of
patients under the age of 70 with results of those aged 70
and older. Furthermore, we compare the HRQL and health
care utilisation of these younger and older survivors with that
of an age- and gender-matched normative population. Be-
cause our previous articles on long-term prostate cancer,
endometrial cancer and non-Hodgkin’s lymphoma survivors
did not focus especially on the elderly, we combined the data
of these studies in this study.4–62.1. Setting and participants
A population-based, cross-sectional survey was conducted at
the Eindhoven Cancer Registry (ECR). The ECR records data on
all patients newly diagnosed with cancer in the southern part
of the Netherlands, an area with 2.3 million inhabitants, 10
hospitals, with 18 hospital locations and two radiotherapy
institutes.11 The ECR was used to select all patients diagnosed
with prostate cancer or endometrial cancer between 1994 and
1998 and all patients diagnosed with non-Hodgkin’s lym-
phoma between 1989 and 1998. Data on NHL were collected
over a longer period of time because negative side-effects of
NHL often occur at a later stage.
Participants older than 75 years at diagnosis were excluded
as it was expected that they would have difficulty in complet-
ing a self-report questionnaire without assistance. However,
as the questionnaire was distributed 5–15 years after diagno-
sis we were still able to include large numbers of elderly. To
exclude all persons who had died before November 1st,
2004, our database was linked to the database of the Central
Bureau for Genealogy, which collects data on all deceased
Dutch citizens via the civil municipal registries. After having
excluded all persons who had died, data collection was
started in November 2004. Approval for this study was ob-
tained from a local certified Medical Ethics Committee.
2.2. Data collection
Medical specialists sent their (former) patients a letter to in-
form them about the study, together with the questionnaire.
The letter explained that, by returning the completed ques-
tionnaire, the patient agreed to participate and consented to
linkage of the questionnaire data with their disease history
as registered in the ECR. Patients were reassured that
non-participation would not have any consequences for their
follow-up care or treatment. If the questionnaire was not re-
turned within two months, a reminder-letter with an addi-
tional copy of the questionnaire was sent.
2.3. Measures
The ECR routinely collects data on tumour characteristics,
including date of diagnosis, grade, clinical stage,12 treatment
and patient background characteristics like date of birth.
The questionnaire also included questions on sociodemo-
graphic data, including marital status, current occupation,
educational level as well as disease progression and current
comorbidity.
The Dutch version of the SF-36 questionnaire was used to
assess HRQL.13 It incorporates two composite scales – the
Physical Component Scale (PCS) and the Mental Component
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tioning (PF), role limitations due to physical health problems
(RP), bodily pain (BP), general health perceptions (GH), vitality
(VT), social functioning (SF), role limitations due to emotional
problems (RE) and general mental health (MH).15 The internal
consistency reliability estimates of all scales were above the
criteria recommended for group comparisons (Cronbach’s
a = 0.70). According to standard scoring procedures, all scales
were linearly converted to a 0–100 scale, with higher scores
indicating better functioning.
The SF-36 has been shown to be a valid measure of HRQL
in a population more than the age of 70 years.16 Furthermore,
the SF-36 is able to discriminate between patients who had a
diagnosed malignancy and patients who did not have a
known cancer diagnosis.17 We used Norman’s ‘rule of thumb’
that the threshold of discrimination for changes in HRQL for a
chronic disease appears to be approximately half a SD.18
The SF-36 scores of the patient sample were compared
with those of an age-matched normative sample. This age-
matched sample was drawn from a nationwide sample of
Dutch adults (n = 1742) in which questionnaires were mailed
to a sample of households drawn at random from the na-
tional telephone registry.15 The SF-36 was mailed to 2800
households. Non-respondents were sent reminder letters
after 2 months and 3 months following the initial mailing.
In total, 1771 questionnaires were returned, representing a
63% response rate.
This study was done in the Netherlands, a country in
which every person has equal access to care. After treatment,
patients go to their specialist for control visits for a number of
years and this varies by site. Endometrial cancer survivors are
followed up until 5 years after diagnosis. Prostate cancer pa-
tients are followed up until 10 years after diagnosis. Patients
with non-Hodgkin’s lymphoma are in follow-up for at least
5 years. However, it is well accepted to keep them under spe-
cialist surveillance for a longer period of time (Dutch guide-
lines; http://www.oncoline.nl).
The items concerning health care utilisation included
questions on the number of visits to a general practitioner
(e.g. primary care physicians) and medical specialist (includ-
ing those specialists involved in cancer care) in the past 12
months. These questions were asked in a similar way as is
done via the annual monitoring of the health care situation
of a random sample (N = ±10,000) of the Dutch population
by Statistics Netherlands (http://statline.cbs.nl). Furthermore,
patients were asked the following question; ‘After cancer treat-
ment, did you receive any additional care for cancer-related
problems? If yes, please indicate the kind of additional care
from the list below’. The list included a dietician, psycholo-
gist, sexologist, pastoral care, creative therapy, recovery pro-
gramme, oncology nurse, physiotherapist and contact with
other cancer survivors.
2.4. Statistical analyses
All statistical analyses were performed using SAS (version 9.1
for Windows, SAS institute Inc., Cary NC). Routinely collected
data from the ECR on patient and tumour characteristics
enabled us to compare the group of respondents, non-respon-
dents and patients with unverifiable addresses, using the v2-test for categorical variables. Sociodemographic and clinical
characteristics of patients with different types of cancer are
given in percentages.
Linear regression analyses were carried out in order to
investigate the association between patient characteristics
(age, comorbidity) and tumour characteristics (stage, treat-
ment, time since diagnosis) with the composite and subscale
scores of the SF-36. On the basis of the univariate results,
multivariate models were constructed to determine which
of the patient and tumour characteristics were associated
independently with HRQL outcomes. We controlled for these
variables in the analysis of covariance (ANCOVA), which
was used to compare means of SF-36 scores between different
age groups.
Multivariate linear regression analyses were carried out to
investigate the independent association between sociodemo-
graphic (age, comorbidity, marital status, education and occu-
pation) and clinical variables (time since diagnosis, stage,
grade, treatment) and the SF-36 scale scores, using a p-value
of <0.01 as statistically significant. We applied multivariate
regression analyses in both age groups separately as we were
interested to see if different factors would be associated with
HRQL in older and younger survivors. Because the choice of
treatment is associated strongly with age, we hypothesised
that treatment would have a different association with HRQL
in younger than in older survivors. The independent variables
were categorised as follows. Age and time since diagnosis
were entered as continuous variables. Tumour stage was en-
tered as stages I (reference category), II, III, IV, unknown. Ther-
apies were entered as therapies (reference category) versus no
therapies, for example radiotherapy versus no radiotherapy.
Comorbidity was entered as comorbidity (reference category)
versus no comorbidity. Marital status was entered as married
(reference category), not married, divorced. Education was en-
tered as high (reference category) versus low. Occupation was
entered as work (reference), no work, retired.
The percentages of patients visiting a general practitioner
or medical specialist in the past 12 months were compared to
the percentage of people from the general population visiting
these health care professionals. This comparison was made
according to the type of tumour and according to the age at
the time of answering the questionnaire; for both survivors
younger than 70 and those older than 70 years of age an
age- and gender-matched reference group from the general
population was formed. Percentages were compared using
binomial distributions.
3. Results
3.1. Sociodemographic and medical characteristics
One thousand three hundred and seventy nine (80%) of 1729
patients returned a completed questionnaire (Fig. 1). A com-
parison of respondents, non-respondents and patients with
unverifiable addresses indicated that the non-respondents
were significantly older, more often diagnosed with stage I
disease and less often treated with chemotherapy than
respondents (Table 1). A number of these respondents were
excluded from the primary analyses because they exhibited
disease progression (90 new primary tumour, 110 metastasis
4273 patients < 75 years diagnosed and registered with cancer  
between 1989 and 1998 and living in the region of CCCS
Specialists from 18 hospital locations received an invitation letter
to participate in this study.  
Addresses of the remaining 1997 patients were checked for
correctness.
A questionnaire was sent to the remaining 1729 patients.  
Two hospital departments declined to 
participate: 148 patients. 
268 (13%) addresses could not be 
verified. 
1379 patients returned a completed questionnaire (80%). 
Still alive in November 2004: 2145 (50%) patients.
350 (20%) patients did not complete 
the questionnaire of which 96 patients 
had a known reason: 
-Actively refused (n=36) 
-Too ill or incompetent (n=16) 
-Hospitalized/institutionalized (n=24) 
-Did not know they had cancer (n=16)  
A number of patients were excluded from final analyses because 
they exhibited disease progression (90 new primary tumour, 110 
metastasis and 158 recurrence) leaving 1112 patients to be 
analysed. 
−
Fig. 1 – Flow-chart of the data collection process.
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Sociodemographic and clinical characteristics of cancer sur-
vivors, according to age group and type of tumour, are pre-
sented in Table 2. In patients with indolent lymphoma, the
disease will be recurrent or progressive, dependent on the
grade of remission induced by treatment (complete or partial
remission). This is different from aggressive lymphoma,
where cure is the aim and a possible treatment result. In this
study, 4 patients (2%) were diagnosed with uncommon non-
Hodgkin lymphoma, 58 patients (26%) were diagnosed with
indolent lymphoma, 137 patients (61%) with aggressive lym-
phoma and 26 patients (12%) were diagnosed with another
or unknown grade.
3.2. Young versus old cancer survivors
Young non-Hodgkin lymphoma survivors reported higher
scores on the subscales physical functioning (77.4 versus
60.5; p < 0.01) compared to older lymphoma survivors (Table
3) and this difference was clinically meaningful. Differences
were also found for mental health, role-physical functioning
and the physical and mental component scales but although
they were statistically significant, they were not clinically
meaningful.Young endometrial cancer survivors experienced higher
scores on the subscales physical functioning (77.2 versus
51.2; p < 0.001), role-physical functioning (71.5 versus 51.1;
p < 0.05), and on the physical component scale (47.6 versus
39.7; p < 0.001) compared to older endometrial cancer survi-
vors and these differences were also clinically meaningful.
Young prostate cancer survivors reported higher scores on
the subscale physical functioning (77.7 versus 65.1; p < 0.001)
compared to older prostate cancer survivors and this effect
was clinically meaningful (Table 3). Furthermore, young pros-
tate cancer survivors reported higher scores on mental
health, role-physical functioning, and the physical and men-
tal component scales compared to older survivors but these
effects were only statistically significant and not clinically
meaningful.
3.3. Cancer survivors versus a normative population
Non-Hodgkin lymphoma survivors under the age of 70 were
less vital (61.4 versus 68.8; p < 0.01), experienced less bodily
pain (81.6 versus 72.4; p < 0.01) and a lower general health per-
ception (57.6 versus 68.6; p < 0.001) compared to an age- and
gender-matched normative population and these differences
were clinically meaningful (Fig. 2). Lymphoma survivors aged








addresses, N = 268
Mean age at time of survey 70 years 71 years 67 years
Age at time of survey
<65 years 347 (25) 69 (20) 82 (31) 0.0029
65–75 years 534 (39) 123 (35) 98 (37)
75+ years 498 (36) 158 (45) 88 (33)
Years since diagnosis
5–9 years 1241 (90) 310 (89) 230 (86) 0.1216
10–15 years 138 (10) 40 (11) 38 (14)
Stage at diagnosis
I 594 (43) 189 (54) 114 (43) 0.0002
II 528 (38) 97 (28) 88 (33)
III 61 (4) 20 (6) 18 (7)
IV 127 (8) 20 (6) 25 (9)
Unknown 69 (5) 24 (7) 23 (9)
Treatment
Surgery 718 (52) 199 (57) 129 (48) 0.0906
Radiotherapy 552 (40) 127 (36) 96 (36) 0.2453
Hormonal therapy 211 (15) 51 (15) 30 (11) 0.2195
Chemotherapy 212 (15) 37 (11) 47 (18) 0.0317
Wait and see 84 (6) 24 (7) 24 (9) 0.2205
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population.
Endometrial cancer survivors under the age of 70 experi-
enced less bodily pain compared to the age- and gender-
matched normative population (76.8 versus 68.0; p < 0.001)
and this effect was clinically meaningful. Furthermore, they
reported higher scores on physical functioning and the phys-
ical component scale but these effects were only statistically
significant and not clinically meaningful. Endometrial cancer
survivors aged 70 and older did not differ significantly from
the normative population.
Prostate cancer survivors under the age of 70 were com-
pared with an age- and gender-matched normative popula-
tion and they reported less bodily pain (82.7 versus 72.5;
p < 0.001), which was clinically meaningful. Furthermore, sur-
vivors aged 70 and older reported lower scores on general
health perception and reported less bodily pain but these ef-
fects were only statistically significant and not clinically
meaningful.
3.4. Multivariate linear regression analyses
The results of the multivariate linear regression analyses,
with the SF-36 scales as outcome variables, are reported as
beta coefficients for patients <70 and P70 years. In cancer
survivors younger than 70, comorbidity was negatively asso-
ciated with the majority of the SF-36 subscales (Table 4). Fur-
thermore, education was positively associated with physical
functioning and occupation was positively associated with
role-physical functioning, role-emotional functioning and
general health perception. In older cancer survivors, age
was negatively associated with physical functioning, role-
physical functioning, social functioning, role-emotional func-tioning and the physical component scale. Comorbidity was
negatively associated with all SF-36 subscales. And finally,
occupation was positively associated with general health,
vitality and the physical component scale.3.5. Health care utilisation
The percentage of people having contact with a general prac-
titioner and a medical specialist in the past 12 months was
compared between young (<70) and old (P70) cancer survi-
vors (non-Hodgkin lymphoma, endometrial cancer and pros-
tate cancer) with an age- and gender-matched normative
population (Table 5). The percentage of cancer survivors
who visited their general practitioner was comparable to that
of the general age-matched normative population for both
younger and older survivors. However, the percentage of sur-
vivors who visited their medical specialist was significantly
higher compared to the age- and gender-matched sample
from the normative population and this holds for both the
younger and older age groups. Cancer survivors only sporad-
ically (0–4%) used the following additional care services after
cancer treatment: dietician, psychologist, sexologist, social
worker, pastor, creative therapy, recovery programme, oncol-
ogy nurse, physiotherapist and contact with other cancer sur-
vivors (data not shown). There were no differences in use of
additional care services between younger and older cancer
survivors.4. Discussion
The aim of the present study was to describe the HRQL and
health care utilisation among long-term cancer survivors
Table 2 – Sociodemographic and medical characteristics of long-term cancer survivors without recurrent disease or new
primary malignancies
N (%)













Mean age 53 76 63 76 66 77
Gender
Male 83 (54) 33 (47) 0 (0) 0 (0) 135 (100) 469 (100)
Female 72 (46) 37 (53) 177 (100) 106 (100) 0 (0) 0 (0)
Stage at diagnosis
I 56 (36) 35 (50) 157 (89) 92 (87) 42 (31) 130 (28)
II 34 (22) 15 (21) 9 (5) 13 (12) 79 (59) 276 (59)
III 16 (10) 3 (4) 6 (3) 1 (1) 5 (4) 13 (3)
IV 41 (26) 11 (16) 1 (1) 0 (0) 5 (4) 20 (4)
Unknown 8 (5) 6 (9) 4 (2) 0 (0) 4 (3) 30 (6)
Primary treatmenta
Surgery 22 (12) 6 (14) 221 (99) 59 (98) 188 (64)* 108 (35)
Radiotherapy 85 (46) 17 (40) 68 (30) 23 (38) 113 (39)* 163 (52)
Hormonal therapy 0 (0) 0 (0) 1 (1) 0 (0) 20 (15)* 133 (28)
Chemotherapy 115 (74) 45 (64) 4 (2) 0 (0) 0 (0) 0 (0)
Wait and see 12 (8) 4 (6) 0 (0) 0 (0) 5 (4) 33 (7)
Comorbidity * *
None 92 (50) 11 (26) 62 (28) 16 (27) 120 (41) 103 (33)
1 or more 91 (50) 31 (74) 161 (72) 44 (73) 173 (59) 208 (67)
Most frequent comorbid conditions
1. Hypertension 22 (14)* 22 (31) 56 (32)* 48 (45) 36 (27) 138 (29)
2. Arthrosis 25 (16)* 23 (33) 65 (37) 42 (40) 28 (21) 107 (23)
3. Asthma 12 (8) 9 (13) 21 (12) 11 (10) 13 (10) 71 (15)
Marital status * * *
Married 112 (75) 39 (60) 128 (74) 46 (46) 110 (85) 352 (79)
Not married/divorced 30 (20) 9 (14) 20 (12) 7 (7) 12 (9) 24 (5)
Widowed 7 (5) 17 (26) 24 (14) 46 (46) 7 (5) 72 (16)
Educational level * * *
Primary school 56 (38) 38 (59) 90 (52) 72 (74) 44 (34) 216 (49)
Secondary school 49 (33) 18 (28) 62 (36) 18 (19) 45 (35) 145 (33)
College/university 42 (29) 8 (13) 21 (12) 7 (7) 41 (32) 82 (19)
Occupation * *
Employed 67 (45) 0 (0) 30 (17) 3 (3) 20 (16) 6 (1)
Unemployed 47 (32) 12 (18) 86 (50) 50 (51) 10 (8) 6 (1)
Retired 34 (23) 53 (82) 57 (33) 45 (46) 99 (77) 418 (94)
The reported characteristics all refer to the time of survey unless stated otherwise.
a Patients can be treated with a combination of treatments, therefore, the percentages do not add up to one hundred.
* p < 0.05 difference between those <70 years of age and those 70 years and older.
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years of age and to an age-matched normative population.
HRQL of older and younger survivors is comparable, with
the exceptions of physical functioning which is lower in older
survivors. This difference in physical functioning was proba-
bly age-related and not caused by cancer because physical
functioning among survivors did not differ much from an
age-matched normative population. Both younger and older
long-term cancer survivors visited their medical specialist of-
ten but used additional care services after cancer treatment
only sporadically.
Young non-Hodgkin lymphoma survivors, but not prostate
and endometrial cancer survivors, reported a somewhatlower HRQL compared to the normative population while old-
er cancer survivors did not report lower scores compared to
the norm. Our results contradict the results of a study on can-
cer and non-cancer patients in Medicare managed care that
showed that both younger (65–74 years) and older (P75 years)
cancer survivors had significantly (p < 0.0001) lower scores on
all SF-36 subscales compared to younger (65–74 years) and
older (P75 years) non-cancer patients.19 Although these
effects were statistically significant, it is unknown if they
were clinically meaningful because subscales were not line-
arly converted to a 0–100 scale according to standard scoring
procedures.20 For this reason, our scores can not be compared








PF RP RE VT MH SF BP GH PCS MCS PF RP RE VT MH SF BP GH PCS MCS
PF RP RE VT MH SF BP GH PCS MCS PF RP RE VT MH SF BP GH PCS MCS
PF RP RE VT MH SF BP GH PCS MCS PF RP RE VT MH SF BP GH PCS MCS
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Prostate cancer survivors Normative population
***







Prostate cancer survivors Normative population
** *
*p<0.05; **p<0.01; *** p<0.001 
Fig. 2 – Unadjusted SF-36 subscale scores: survivors versus an age- and gender-matched normative population according to
age groups.
Table 3 – Mean SF-36 scores and standard deviation (SD) for long-term survivors according to age (<70, P70) at time of
questionnaire
SF-36 scales Mean (SD)













Physical functioning 77.4 (23.8)** 60.5 (28.1) 77.2 (21.3)*** 51.2 (29.6) 77.7 (23.0)*** 65.1 (28.3)
Role-physical 67.3 (41.3)** 61.4 (43.8) 71.5 (39.7)* 51.1 (42.3) 74.0 (37.7)** 63.7 (42.9)
Role-emotional 84.7 (31.8) 72.9 (40.2) 76.5 (38.1)** 64.0 (45.8) 77.8 (37.9) 75.5 (39.4)
Vitality 61.4 (21.4) 61.1 (19.0) 65.4 (19.0) 61.1 (18.1) 68.4 (21.7) 66.5 (20.7)
Mental health 77.3 (16.3)* 76.4 (18.4) 72.9 (17.3) 75.5 (18.1) 75.7 (17.4)* 77.6 (18.5)
Social functioning 81.7 (20.9) 77.5 (25.2) 81.9 (19.9) 78.3 (23.0) 84.4 (21.0) 80.9 (23.7)
Bodily pain 81.6 (22.3) 77.6 (24.8) 76.9 (22.8) 70.9 (26.0) 82.7 (21.6) 79.7 (23.5)
General health perception 57.6 (24.8) 57.5 (19.9) 63.6 (20.3) 59.1 (19.7) 62.4 (20.6) 59.3 (19.7)
Physical component scale 45.7 (11.5)*** 42.2 (10.3) 47.6 (9.8)*** 39.7 (11.5) 47.8 (10.0)*** 44.0 (10.7)
Mental component scale 52.2 (8.9)*** 51.9 (10.2) 50.4 (9.8) 52.4 (10.3) 51.6 (10.4)*** 53.6 ( 9.2)
* p < 0.05.
** p < 0.01.
*** p < 0.001; difference between those <70 years of age and those 70 years and older. p-Value was adjusted for stage, age at diagnosis,
treatment, time since diagnosis, education, marital status and comorbidity.
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Table 4 – Multivariate linear regression model evaluating independent variables for SF-36 subscale scores
Independent variable SF-36 subscalesa
PF RP BP GH VT SF RE MH PCS MCS
<70 year
Age (time of questionnaire) NS NS NS NS NS NS NS NS NS NS
Time since diagnosis NS NS NS NS NS NS NS NS NS NS
Non-Hodgkin’s lymphoma NS NS NS NS NS NS NS NS NS NS
Prostate cancer NS NS NS NS NS NS NS NS NS NS
Endometrial cancer NS NS NS NS NS NS NS NS NS NS
Tumour stage NS NS NS NS NS NS NS NS NS NS
Radiotherapy NS NS NS NS NS NS NS )0.12* NS NS
Surgery NS NS NS NS NS NS NS NS NS NS
Chemotherapy NS NS NS NS NS NS NS NS NS NS
Hormonal Therapy NS NS NS NS NS NS NS NS NS NS
Wait and see NS NS NS NS NS NS NS NS NS NS
Comorbidity )0.22*** )0.24*** )0.29*** )0.25*** )0.17*** )0.19*** )0.11* NS )0.31*** NS
Marital status NS NS NS NS NS NS NS NS NS NS
Education 0.17*** NS NS NS NS NS 0.11* NS NS NS
Occupation 0.10* 0.14** NS 0.16** NS NS 0.15* 0.12* NS 0.12*
P70 year
Age (time of questionnaire) )0.22*** )0.14** NS )0.09* )0.10* )0.11** )0.12** NS )0.15** NS
Time since diagnosis NS NS NS NS NS NS NS NS NS NS
Non-Hodgkin’s lymphoma NS NS NS NS NS NS NS NS NS NS
Prostate cancer NS NS NS NS NS NS NS NS NS NS
Endometrial cancer NS NS NS NS NS NS NS NS NS NS
Tumour stage NS NS NS NS NS NS NS NS NS NS
Radiotherapy NS NS NS NS NS NS NS NS NS NS
Surgery NS NS NS NS NS NS NS NS NS NS
Chemotherapy NS NS NS NS NS NS NS NS NS NS
Hormonal Therapy NS NS NS NS NS NS NS NS NS NS
Wait and see NS NS NS NS NS NS NS NS NS NS
Comorbidity )0.17*** )0.17*** )0.24*** )0.23*** )0.20*** )0.15*** )0.09* )0.12** )0.20*** )0.14**
Marital status NS NS NS NS NS NS NS NS NS NS
Education NS NS NS NS NS NS NS NS NS NS
Occupation NS 0.10* NS 0.11** 0.11** NS NS NS 0.12** NS
SF-36, short form-36; PF, physical functioning; RP, role limitations physical health; BP, bodily pain; GH, general health; VT, vitality, SF, social
functioning; RE, role limitations emotional problems; MH, mental health; PCS, physical component scale; MCS, mental component scale.
a Standardised beta coefficients.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
Table 5 – The percentage of contact within the last 12 months with a general practitioner and medical specialist between
cancer survivors and an age-matched normative population













% Visited general practitioner
Survivors 82 95 91 92 89 88
Controls 78 88 85 89 82 86
% Visited specialist
Survivors 87*** 92** 71** 71** 91*** 94***
Controls 48 61 54 58 61 63
Data collected by Statistics Netherlands in 2003.
*p < 0.05; **p < 0.01; p < 0.001; difference between survivors and controls.
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sons with and without cancer.21 Results of that study showed
that cancer patients (>75 years) reported lower scores on the
SF-12 physical and mental component scales compared to anormative population without cancer. However, these differ-
ences were only statistically significant and not clinically
meaningful. Furthermore, this study included patients with
cancer and not cancer survivors and therefore is not easily
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indirectly confirmed the findings from our multivariate linear
regression model. Advanced age had the same main effect in
breast cancer survivors (n = 173) as well as in a matched con-
trol group (n = 176). Namely, a greater number of diagnosed
medical conditions caused limitations in activities.22
Long-term prostate and endometrial cancer survivors re-
ported lower pain levels compared to the normative popula-
tion. We suspect that this is either a chance finding or, if
real, may reflect a ‘response shift’ phenomenon whereby
individuals redefine their internal standards for rating their
level of functioning or symptoms (in this case pain) as a result
of their illness experience.5,23,24 Patients may accept pain as
an inevitable consequence of having been treated for cancer,
a condition they perceive as life threatening. Common benign
aches and pains, such as headache, may then be considered
as less burdensome by cancer survivors than by their general
population counterparts.
Furthermore, this study showed that HRQL in endometrial
and prostate cancer survivors was comparable, and not lower,
compared to a normative population. This can be explained
by the fact that most people not only experience negative
but also certain positive effects after an encounter with a
stressor.25–31 This is also known as ‘benefit finding’ which
can be described as the identification of benefit from adver-
sity.32 Furthermore, patients may experience posttraumatic
growth31,33–37 which is described as ‘the experience of signif-
icant positive change arising from the struggle with a major
life crisis’.38 Benefit finding and posttraumatic growth may
explain, at least in part, the absence of differences in HRQL
between prostate and endometrial cancer survivors com-
pared to the age-matched norm population.
Older long-term cancer survivors experienced a lower
physical functioning compared to younger survivors. This dif-
ference between older and younger survivors was confirmed
by a study among cancer survivors that compared survivors
aged 65–74 (n = 22.106) to those aged 75 and older
(n = 21.651). Individuals aged 65-74 had significantly higher
mean scores on all SF-36 scales compared to those aged 75
and older.19 This difference was also indirectly confirmed by
a study that compared differences in HRQL by therapy for
both young (<75) and old (P75) long-term prostate cancer sur-
vivors. Although this study only showed mean SF-36 scores
for both young and old survivors by therapy and did not test
for significance between the two, the big differences in mean
scores between old and young survivors on some subscales
are definitely an indication4.
Both younger and older cancer survivors visited their med-
ical specialist, but not their general practitioner, more often
compared to the general population. These same results were
also found in another article based on this database.39 How-
ever, in that particular study, we did not make a difference
for age groups. A difference in survivors under and above
the age of 75 was made in a Dutch study among 10-year
breast cancer survivors and the results confirm our findings.40
The proportion of both younger and older breast cancer survi-
vors, who visited a medical specialist in the past 12 months,
was significantly higher compared to controls while there
were no differences in visits to a general practitioner. Finally,
our results partly confirm the results of a Norwegian studyamong long-term cancer survivors.41 The use of specialist
health care services was significantly higher among cancer
survivors (49%) than among controls (27%) and this difference
remained, even 10 years after diagnosis, while the frequency
of visiting a general practitioner normalised over time.
The high proportion of survivors who visited a medical
specialist in the past 12 months compared to the normative
population can partly be explained by routine annual fol-
low-up examinations. For example, patients with non-Hodg-
kin’s lymphoma are in follow-up for at least 5 years (Dutch
guidelines; http://www.oncoline.nl). However, most of them
stay longer in follow-up. Additionally, prostate cancer pa-
tients visit their urologists only 10 years after diagnosis for
annual follow-up. These follow-up examinations explain, at
least in part, the higher proportion of survivors visiting a
medical specialist as compared to the general population.
In our questionnaire, we asked patients whether they re-
ceived any additional care for cancer-related problems after
cancer treatment. Survivors only sporadically received addi-
tional support. However, the survivors in our study were diag-
nosed and treated between 1989 and 1998. Additional care
after cancer treatment was not common in those days. It
would be interesting to ask the same question to patients
diagnosed and treated nowadays in order to estimate the in-
crease in the percentage of survivors receiving additional care
after cancer.
Several limitations of the current study should be noted.
First, only 13% of patients could not be sent a questionnaire
because of unverifiable addresses and 20% of patients who
were sent a questionnaire did not respond, so we do not
know what their current health status is. Non-respondents
were significantly older; more often diagnosed with stage I
disease and less often treated with chemotherapy than
respondents or patients with unverifiable addresses. It is
therefore possible that our results cannot be generalised to
very old patients, patients diagnosed with stage I disease
and patients treated with chemotherapy. Second, patients
with disease progression were excluded from our analysis.
Information on HRQL of these patients is therefore lost.
However, we experienced difficulties in reporting HRQL of
this heterogeneous subset of patients because additional tu-
mour characteristics for disease progression (e.g., localisa-
tion, stage, grade and time since diagnosis) were unknown.
Our results can only be generalised to survivors with the
best prognosis namely, those who do not show any signs
of disease progression. Third, it is more difficult to draw con-
clusions from a cross-sectional study than a longitudinal
study. No conclusions can be drawn on the nature and direc-
tion of the relationships. Since we only included disease-free
survivors in our analyses, we cannot generalise the results
of our study to those who have disease progression. Fourth,
we excluded patients aged 75 and older at diagnosis because
it was expected that they would have difficulty in complet-
ing a self-report questionnaire without assistance. However,
important information on the HRQL and health care utilisa-
tion among the very elderly is now missing. Offering the el-
derly assistance with completing the questionnaire, like
giving information by telephone, completing the interview
by telephone, or offering house-visits by a research assistant
who would help them to fill out the questionnaire could
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ly, we measured HRQL with the SF-36. However, it is also
important that assessment of HRQL incorporates issues of
importance to individual older people by broadening the
scope of the measurement instruments, thus representing
more validly the HRQL status of older patient groups.42
Despite these limitations, the results of this study form an
important contribution to the limited information available
on HRQL and health care utilisation in the growing group of
elderly long-term cancer survivors. This study included an
unselected group of cancer patients, treated in various gen-
eral hospitals, and not in centres of excellence or tertiary
referral centres in contrast to most randomised trials. Results
of a population-based study can more easily be generalised to
the general population compared to results of randomised
controlled trials. In addition, the large number of participants
in this study and the high response rate of this study allow us
to extrapolate to the broad population of long-term cancer
survivors without disease progression.
Our study provided insight into the HRQL and health care
utilisation of elderly long-term cancer survivors. HRQL of old-
er and younger survivors is comparable, with the exceptions
of physical functioning which is lower in older survivors. This
difference in physical functioning was probably not caused by
cancer because physical functioning among cancer survivors
did not differ much compared to an age-matched normative
population. This can be explained in numerous ways. For
example, lower HRQL among elderly survivors compared to
younger survivors can be due to a natural ageing process. In
addition, a lower HRQL between young survivors and the
(young) normative population can be caused by the fact that
these patients were relatively ‘healthy’ at diagnosis and thus
were treated more aggressively compared to older cancer sur-
vivors who were more fragile. Older cancer patients were
probably treated less aggressively and therefore do not differ
much from the (old) normative population. Furthermore, it is
possible that older cancer survivors experience the same
HRQL compared to the normative population because only
the most though survivors survive while the more weaker pa-
tients have already died; ‘survival of the fittest’.Conflict of interest statement
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